Isabel Huber
CEO and co-founder
SUCCIPRO
Tarragona, Spain
AI‑engineered enzyme SD1253 lowers gut succinate to reduce inflammation, offering a first‑in‑class, disease‑modifying oral therapy for IBD.
My organisation
About me
Pharmacist with a PhD in Biochemistry (University of Barcelona, Spain),I trained at VHIO and later joined Mosaic Biomedicals, a VHIO spin-off whose cancer therapy was licensed to AstraZeneca. In 2018, I became Head of Innovation at IISPV’s DIAMET group, managing patents and preclinical strategies while completing an MBA. Recognized among the top 10 female entrepreneurs in Catalonia (EAE Business School, 2024) and awarded 4th place (among 149 projects worldwide) at the global Women Entrepreneur Competition (TARA Foundation), I now lead SUCCIPRO, for which I have raised 2,6 M€ in dilutive and non-dilutive funding.